Hungarian pharmaceutical company Gedeon Richter announced on Tuesday the acquisition of the women's health discovery portfolio of US-based biotech company Celmatix. The portfolio includes assets targeting fertility, endometriosis and ovarian ageing. The development of the acquired programmes will be led by Richter's women's health R+D hub in Belgium. Celmatix will receive an upfront payment and […]
Hungarian pharmaceutical company Gedeon Richter on Wednesday said it signed a strategic research collaboration and option-to-license agreement with Swiss biotech company FimmCyte. Richter said the partnership aims to advance the development of FimmCyte's FMC2 antibody for the treatment of endometriosis. The parties have negotiated an exclusive and worldwide license agreement for the future development and […]
Gedeon Richter Plc. and Fuji Pharma Co., Ltd. have announced the expansion and further strengthening of their long-standing strategic collaboration. The two companies have been enjoying a strong partnership in Women’s Healthcare (WHC), according to a statement published on the website of the Budapest Stock Exchange. This collaboration is exemplified by Fuji’s development, launch and […]
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of Hungarian pharmaceutical company Gedeon Richter's drug FYLREVY as hormone replacement therapy for estrogen deficiency symptoms, Richter said on Friday. The European Commission will review the CHMP recommendation for a final decision […]
Net income of Hungarian pharmaceutical company Gedeon Richter fell 7% year-on-year to HUF 163.3bn in Q1-Q3, dropping on a financial loss, an earnings report posted ahead of the opening bell on Thursday shows. Revenue rose 7% to HUF 680.2 billion and operating profit climbed 8% to HUF 204.5 billion. A net financial loss of HUF […]
Gedeon Richter Plc. and Hikma Pharmaceuticals Plc. along with its wholly owned subsidiary Hikma Pharmaceuticals USA Inc. (“Hikma”) announcee this Monday that the U.S. Food and Drug Administration (FDA) has granted approval for the Biologics License Applications (BLA) of their biosimilar denosumab products, EnobyTM (denosumab-qbde) and XtrenboTM (denosumabqbde), referencing Prolia® and Xgeva®, respectively. Denosumab is […]
Gedeon Richter Plc.'s performance in the first half of the year was in line with its annual plans, so it has not changed its expectations for this year, CEO Gábor Orbán said at a press conference following the flash report on Wednesday in Budapest. He said that, excluding exchange rate effects, they expect growth of […]
The Hungarian pharma company Gedeon Richter Plc.'s consolidated sales revenue for the first half of the year was HUF 465.5 billion, 10.9% higher than a year earlier, the company announced on the Budapest Stock Exchange (BÉT) website on Wednesday. Net profit for the first half of 2025 was HUF 120 billion, which is 13% lower […]
The Hungarian pharmaceutical company Gedeon Richter Plc. has announced on the website of the Budapest Stock Exchange that “understanding and supporting the Hungarian government's efforts to reduce the burden on patients, voluntarily restricts the price of its non-prescription product Panangin®, a magnesium and potassium dietary supplement and complementary treatment for chronic heart disease and cardiac […]
The consolidated revenue of Gedeon Richter Plc. was HUF 224 billion in the first quarter, up 10% year-on-year, the pharmaceutical company announced on the website of the Budapest Stock Exchange (BSE) on Tuesday. The company posted a profit after tax of HUF 68.1 billion in the first quarter, similar to the previous year. According to […]
The pharmaceutical company Richter Gedeon Plc.'s new central office building, the Richter Center, situated in Budapest's 10th District, has received prestigious real estate market recognition, winning the Headquarters of the Year Award in the 2025 Office of the Year competition, the company told MTI on Friday. The statement said that the 17,400-square-meter, six-story headquarters building, […]
Budapest-based pharmaceutical company Gedeon Richter Plc. has received positive opinion from CHMP for marketing authorization for Junod and Yaxwer, its biosimilar denosumab products for bone disease and osteoporosis. Budapest-based pharmaceutical company Gedeon Richter Plc. has announced on the website of the Budapest Stock Exchange that it received a positive opinion from the Committee for Medicinal […]
The Hungarian pharmaceutical company Gedeon Richter Plc. has announced on the website of the Budapest Stock Exchange that the European Medicines Agency (EMA) has accepted Richter’s marketing authorization application (MAA) for its proposed biosimilar to RoActemra tocilizumab. Tocilizumab, the first biologic to inhibit IL-6 signaling, is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic […]
Budapest-based pharmaceutical giant Gedeon Richter Plc. announced its Q4/FY 2024 financial results at the website of the Budapest Stock Exchange by stating that 2024 was an active year with business development across all segments, aimed at providing access to health by bringing solutions to unmet needs and by offering affordable medicines to a wide range […]
Gedeon Richter has announced positive topline results from Phase I and Phase III clinical studies for its proposed biosimilar to RoActemra® tocilizumab that has the development code 'RGB-19'. The Hungarian pharmaceutical firm points out in a statement on the webiste of the Budapest Stock Exchange that Phase I clinical study evaluated the equivalence of pharmacokinetics […]
